Advances and Unmet Needs in Hepatocellular Carcinoma
Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.
Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma (HCC).
According to Finn, a lot of the major advances in unresectable HCC have occurred in the past 3 years. Unresectable can be defined as a case that is not curative, including patients undergoing chemoembolization, patients receiving localized or regional treatment who will progress and become candidates for systemic treatment, and patients who presented with cases advanced enough to be treated with systemic treatment upfront.
While there will always be a need for more effective and less toxic treatments, the real knowledge gap exists in the lack of knowledge in how these drugs will perform outside of clinical trials. According to Finn, real-world datasets are needed to draw this conclusion.
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More
